+ Watch NLNK
on My Watchlist
NewLink Genetics Corporation (NLNK) - debt/equity ratio of impressive 0.03. Return on Invested Capital (ROIC) is incredible at 76.85. Price/earnings ratio at 13.5 shows a stock that is not overpriced by any means. Market cap of 1.48B leaves potential for possible acquisition down the road.
NEWLINK GENETIC, ticker NLNK, has a TTM ROE calculated by Zacks of 85,08%. It's one of my LONG picks.
Top 30 rank with min 200M mkt. cap
Ebola is not going away. This stock should shoot up over the next 6 months.
This company appears to be on track in developing products to fight cancer and should be a good buyout candidate.
Newlink is involved in pancreatic cancer drug research. The stock is lifting off.
I laid out the reasons why I think HyperAcute Pancreas will fail here in February: http://caps.fool.com/Pitch/NLNK/6662267/newlinks-most-advanced-clinica.aspxAfter closing my prior underperform for a win I'm back in red and quickly down 12 points. This is a case where I hope I go negative as much as possible because NewLink in looking like a great candidate for puts prior to the interim data expected in mid-2013. I'll keep my ear to the ground for more specific information regarding the data release, which was already pushed back very quietly from April, and update this pitch with put prices and my position, if any.
porto. likededd it.
High risk but potential high reward.
Never has had income. Now with more cash it will? No. Earnings move stocks, not charts.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions